Current Report Filing (8-k)
January 12 2022 - 07:17AM
Edgar (US Regulatory)
0001830214false00018302142022-01-122022-01-120001830214us-gaap:CommonClassAMember2022-01-122022-01-120001830214us-gaap:WarrantMember2022-01-122022-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
January 12, 2022
GINKGO BIOWORKS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
Delaware
|
|
001-40097
|
|
87-2652913
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
27 Drydock Avenue
8th Floor
Boston,
MA
02210
(Address of principal executive offices, including zip
code)
Registrant’s telephone number, including area code:
(877)
422-5362
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Class A common stock, par value $0.0001 per share
|
|
DNA
|
|
NYSE
|
|
Warrants to purchase one share of Class A common stock, each at an
exercise price of $11.50 per share
|
|
DNA.WS
|
|
NYSE
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
Item 2.02.
Results of Operations and Financial Condition.
On January 12, 2022, Ginkgo Bioworks Holdings, Inc. issued a press
release announcing certain preliminary unaudited revenue highlights
and performance updates for the year ended December 31, 2021. A
copy of the press release is furnished with this Current Report on
Form 8-K as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on
Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, regardless of any general incorporation language in
such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
GINKGO BIOWORKS HOLDINGS, INC.
|
|
|
|
|
|
|
Date: January 12, 2022
|
|
By:
|
/s/ Mark Dmytruk
|
|
|
|
Name:
|
Mark Dmytruk
|
|
|
|
Title:
|
Chief Financial Officer
|
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Jun 2022 to Jul 2022
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Jul 2021 to Jul 2022
